Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00339040
First received: June 19, 2006
Last updated: February 24, 2014
Last verified: February 2014
Results First Received: September 7, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Prevention
Conditions: HIV Infections
Sexually Transmitted Diseases
Interventions: Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
Other: Placebo/QHPV

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between October 11, 2006 and November 22, 2006 130 participants were enrolled at 34 clinical sites from US & Puerto Rico.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were stratified by CD4% criteria. Four participants were randomized but did not receive the study treatment. The study analyses were based on 126 participants who received the study treatment.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Participant Flow for 2 periods

Period 1:   Stage I
    Arm A QHPV     Arm B Placebo/QHPV  
STARTED     96     30  
Vaccination 1 at Week 0     96     30  
Vaccination 2 at Week 8     95     30  
Vaccination 3 at Week 24     94     30  
COMPLETED     94     29  
NOT COMPLETED     2     1  
Not able to attend clinic                 1                 0  
Protocol Violation                 1                 1  

Period 2:   Stage II
    Arm A QHPV     Arm B Placebo/QHPV  
STARTED     94     29  
Vaccination 4 at Week 96     84     29  
Vaccination 5 at Week 104     0     28  
Vaccination 6 at Week 120     0     27  
COMPLETED     84     27  
NOT COMPLETED     10     2  
Lost to Follow-up                 3                 0  
Withdrawal by Subject                 1                 2  
Protocol Violation                 3                 0  
Not able to attend clinic                 1                 0  
Site closing                 2                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.
Total Total of all reporting groups

Baseline Measures
    Arm A QHPV     Arm B Placebo/QHPV     Total  
Number of Participants  
[units: participants]
  96     30     126  
Age  
[units: years]
Mean ± Standard Deviation
  10.0  ± 1.4     9.9  ± 1.3     9.9  ± 1.4  
Gender  
[units: participants]
     
Female     53     18     71  
Male     43     12     55  
Race/Ethnicity, Customized  
[units: participants]
     
White, non-Hispanic     4     2     6  
Black, non-Hispanic     54     11     65  
Hispanic     37     14     51  
Others     1     3     4  
Stratification groups [1]
[units: participants]
     
Stratum A     31     10     41  
Stratum B     32     11     43  
Stratum C     33     9     42  
CD4 count  
[units: cells/µL]
Mean ± Standard Deviation
  868  ± 367     1013  ± 455     903  ± 393  
CD4%  
[units: percentage of total lymphocytes]
Mean ± Standard Deviation
  33.9  ± 7.9     35.8  ± 8.6     34.3  ± 8.1  
Log10(RNA)  
[units: Log10(copies/mL)]
Mean ± Standard Deviation
  2.7  ± 0.9     2.6  ± 0.8     2.7  ± 0.9  
RNA group  
[units: participants]
     
≤400 copies/mL     65     22     87  
401 to ≤5000 copies/mL     16     5     21  
>5000 copies/mL     15     3     18  
[1]

STRATIFICATION: Participant were stratified by CD4% criteria into three strata:

  • Stratum A: CD4% Nadir < 15 and CD4% ≥ 15 at screening
  • Stratum B: CD4% Nadir ≥ 15 and < 25 and CD4% ≥ 15 at screening
  • Stratum C: CD4% Nadir ≥ 25 and CD4% ≥ 25 at screening



  Outcome Measures
  Hide All Outcome Measures

1.  Primary:   Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)   [ Time Frame: Within 14 days of first three doses of vaccination ]

Measure Type Primary
Measure Title Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)
Measure Description Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). The grades used are: Grade 1="Mild", Grade 2="Moderate", Grade 3="Severe", Grade 4="Potentially Life-Threatening". All grade 3 and higher signs, symptoms, and laboratory toxicities were included.
Time Frame Within 14 days of first three doses of vaccination  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Any participant who received at least one study vaccine/placebo were included in the safety analysis.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)  
[units: percent of participants]
Number ( 95% Confidence Interval )
  7.3  
  ( 3.0 to 14.5 )  
  6.7  
  ( 0.8 to 22.1 )  


Statistical Analysis 1 for Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)
Groups [1] All groups
Method [2] Fisher Exact
P Value [3] 1.00
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  No text entered.



2.  Primary:   Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment   [ Time Frame: Within 14 days of first three doses of vaccination ]

Measure Type Primary
Measure Title Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment
Measure Description Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities attributed to study treatment were included. The relationship between the Adverse Events and the vaccination were evaluated by study team and assigned to, for example, "Treatment related", "Non-treatment related", "Baseline", "Possibly treatment related".
Time Frame Within 14 days of first three doses of vaccination  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Any participant who received at least one study vaccine/placebo were included in the safety analysis

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment  
[units: percent of participants]
Number ( 95% Confidence Interval )
  0  
  ( 0 to 0 )  
  0  
  ( 0 to 0 )  

No statistical analysis provided for Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment



3.  Primary:   Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion   [ Time Frame: At week 28 after beginning the vaccination series ]

Measure Type Primary
Measure Title Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion
Measure Description Serum anti-HPV 6, 11, 16, and 18 antibody was measured using a competitive Luminex immunoassay (cLIA; reported in milli-Merck Units [mMU]/mL). Sero-positivity was defined as an anti-HPV titer ≥20, 16, 20, and 24 mMU/mL, for HPV types 6, 11, 16, and 18, respectively.
Time Frame At week 28 after beginning the vaccination series  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The type-specific results are reported for participants remaining after exclusion of those with protocol violations, unevaluable specimens, or the presence of type-specific sero-positive antibody at baseline.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion  
[units: percent of participants]
Number ( 95% Confidence Interval )
   
Serotype 6 (n=87, 27)     100.0  
  ( 95.9 to 100.0 )  
  0.0  
  ( 0.0 to 12.8 )  
Serotype 11 (n=90, 27)     100.0  
  ( 95.9 to 100.0 )  
  0.0  
  ( 0.0 to 12.8 )  
Serotype 16 (n=90, 27)     100.0  
  ( 95.9 to 100.0 )  
  3.7  
  ( 0.1 to 19.0 )  
Serotype 18 (n=90, 27)     96.7  
  ( 90.6 to 99.3 )  
  0.0  
  ( 0.0 to 12.8 )  

No statistical analysis provided for Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion



4.  Primary:   Serum Anti-HPV Antibody Titers (cLIA)   [ Time Frame: Arm A week 0, 28, 72, 96, 97, 100; Arm B week 0, 28, 72, 96, 97, 100, 124. ]

Measure Type Primary
Measure Title Serum Anti-HPV Antibody Titers (cLIA)
Measure Description Geometric means of Type-specific Serum anti-HPV antibody titers (cLIA)
Time Frame Arm A week 0, 28, 72, 96, 97, 100; Arm B week 0, 28, 72, 96, 97, 100, 124.  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The type-specific results are reported for participants remaining after exclusion of those with protocol violations, unevaluable specimens, or the presence of type-specific sero-positive antibody at baseline as well as any participants with any missing values at any time points.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
Serum Anti-HPV Antibody Titers (cLIA)  
[units: milli-Merck units [mMU]/mL]
Geometric Mean ( 95% Confidence Interval )
   
Serotype 6 study entry (n=69, 23)     3.8  
  ( 3.5 to 4.1 )  
  4.1  
  ( 3.4 to 4.9 )  
Serotype 6 week 28 (n=69, 23)     544.2  
  ( 395.4 to 749.1 )  
  4.5  
  ( 3.7 to 5.4 )  
Serotype 6 week 72 (n=69, 23)     256.4  
  ( 196.5 to 334.7 )  
  4.3  
  ( 3.6 to 5.1 )  
Serotype 6 week 96 (n=69, 23)     227.9  
  ( 167.3 to 310.3 )  
  4.5  
  ( 3.6 to 5.8 )  
Serotype 6 week 97 (n=69, 23)     1604.8  
  ( 1162.0 to 2216.1 )  
  17.1  
  ( 7.1 to 41.5 )  
Serotype 6 week 100 (n=69, 23)     2473.6  
  ( 1770.2 to 3456.4 )  
  79.7  
  ( 43.7 to 145.3 )  
Serotype 6 week 124 (n=0, 23)     NA  
  ( NA to NA ) [1]
  678.8  
  ( 396.4 to 1162.2 )  
Serotype 11 study entry (n=72, 23)     4.1  
  ( 3.9 to 4.2 )  
  4.0  
  ( 4.0 to 4.0 )  
Serotype 11 week 28 (n=72, 23)     1396.6  
  ( 1103.8 to 1767.1 )  
  4.2  
  ( 3.8 to 4.7 )  
Serotype 11 week 72 (n=72, 23)     313.1  
  ( 234.4 to 418.3 )  
  4.1  
  ( 3.9 to 4.5 )  
Serotype 11 week 96 (n=72, 23)     286.5  
  ( 207.1 to 396.4 )  
  4.0  
  ( 4.0 to 4.0 )  
Serotype 11 week 97 (n=72, 23)     1931.7  
  ( 1389.1 to 2686.3 )  
  11.8  
  ( 5.5 to 25.6 )  
Serotype 11 week 100 (n=72, 23)     3611.2  
  ( 2746.8 to 4747.6 )  
  86.4  
  ( 48.7 to 153.6 )  
Serotype 11 week 124 (n=0, 23)     NA  
  ( NA to NA ) [1]
  1023.0  
  ( 704.2 to 1486.0 )  
Serotype 16 study entry (n=71, 23)     5.5  
  ( 5.5 to 5.5 )  
  5.5  
  ( 5.5 to 5.5 )  
Serotype 16 week 28 (n=71, 23)     5172.5  
  ( 3889.8 to 6878.2 )  
  5.7  
  ( 5.3 to 6.2 )  
Serotype 16 week 72 (n=71, 23)     1126.4  
  ( 788.6 to 1609.0 )  
  5.5  
  ( 5.5 to 5.5 )  
Serotype 16 week 96 (n=71, 23)     1034.5  
  ( 708.8 to 1509.7 )  
  5.5  
  ( 5.5 to 5.5 )  
Serotype 16 week 97 (n=71, 23)     6167.8  
  ( 4391.8 to 8661.8 )  
  12.1  
  ( 5.4 to 27.1 )  
Serotype 16 week 100 (n=71, 23)     11205.6  
  ( 8184.7 to 15341.5 )  
  142.6  
  ( 74.1 to 274.5 )  
Serotype 16 week 124 (n=0, 23)     NA  
  ( NA to NA ) [1]
  4113.8  
  ( 2404.2 to 7039.3 )  
Serotype 18 study entry (n=71, 23)     5.1  
  ( 4.9 to 5.3 )  
  5.0  
  ( 5.0 to 5.0 )  
Serotype 18 week 28 (n=71, 23)     931.2  
  ( 616.7 to 1406.0 )  
  5.0  
  ( 5.0 to 5.0 )  
Serotype 18 week 72 (n=71, 23)     148.2  
  ( 92.5 to 237.4 )  
  5.0  
  ( 5.0 to 5.0 )  
Serotype 18 week 96 (n=71, 23)     142.0  
  ( 86.6 to 232.8 )  
  5.0  
  ( 5.0 to 5.0 )  
Serotype 18 week 97 (n=71, 23)     925.7  
  ( 567.6 to 1510.0 )  
  7.1  
  ( 4.6 to 11.0 )  
Serotype 18 week 100 (n=71, 23)     1530.7  
  ( 991.7 to 2362.4 )  
  18.7  
  ( 10.6 to 32.8 )  
Serotype 18 week 124 (n=0, 23)     NA  
  ( NA to NA ) [1]
  734.3  
  ( 357.3 to 1508.8 )  
[1] Week 124 is not a designated time point for Arm A.

No statistical analysis provided for Serum Anti-HPV Antibody Titers (cLIA)



5.  Secondary:   CD4 Count Over Time   [ Time Frame: Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124. ]

Measure Type Secondary
Measure Title CD4 Count Over Time
Measure Description No text entered.
Time Frame Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Any participant who received at least one study vaccine/placebo and with non-missing CD4 counts.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
CD4 Count Over Time  
[units: cells/µL]
Mean ( 95% Confidence Interval )
   
CD4 count at study entry (n=96, 30)     868  
  ( 794 to 942 )  
  1013  
  ( 843 to 1183 )  
CD4 count at week 8 (n=93, 30)     907  
  ( 830 to 985 )  
  1018  
  ( 851 to 1185 )  
CD4 count at week 12 (n=93, 30)     906  
  ( 828 to 983 )  
  1056  
  ( 830 to 1282 )  
CD4 count at week 24 (n=94, 30)     864  
  ( 792 to 936 )  
  993  
  ( 826 to 1160 )  
CD4 count at week 28 (n=95, 30)     875  
  ( 800 to 950 )  
  959  
  ( 803 to 1115 )  
CD4 count at week 72 (n=88, 30)     823  
  ( 746 to 900 )  
  933  
  ( 768 to 1098 )  
CD4 count at week 96 (n=88, 30)     781  
  ( 712 to 849 )  
  874  
  ( 718 to 1031 )  
CD4 count at week 100 (n=85, 29)     831  
  ( 754 to 907 )  
  924  
  ( 766 to 1083 )  
CD4 count at week 104 (n=0, 27)     NA  
  ( NA to NA ) [1]
  929  
  ( 776 to 1082 )  
CD4 count at week 108 (n=82, 28)     839  
  ( 757 to 921 )  
  980  
  ( 786 to 1174 )  
CD4 count at week 120 (n=0, 28)     NA  
  ( NA to NA ) [2]
  931  
  ( 745 to 1117 )  
CD4 count at week 124 (n=0, 27)     NA  
  ( NA to NA ) [3]
  920  
  ( 728 to 1112 )  
[1] Week 104 is not a designated time point for Arm A.
[2] Week 120 is not a designated time point for Arm A.
[3] Week 124 is not a designated time point for Arm A.

No statistical analysis provided for CD4 Count Over Time



6.  Secondary:   CD4 Percent Over Time   [ Time Frame: Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124. ]

Measure Type Secondary
Measure Title CD4 Percent Over Time
Measure Description No text entered.
Time Frame Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Any participant who received at least one study vaccine/placebo and with non-missing CD4%.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
CD4 Percent Over Time  
[units: percentage of total lymphocytes]
Mean ( 95% Confidence Interval )
   
CD4 percent at study entry (n=96, 30)     34  
  ( 32 to 35 )  
  36  
  ( 33 to 39 )  
CD4 percent at week 8 (n=93, 30)     34  
  ( 32 to 35 )  
  36  
  ( 33 to 39 )  
CD4 percent at week 12 (n=93, 30)     35  
  ( 33 to 37 )  
  37  
  ( 33 to 41 )  
CD4 percent at week 24 (n=94, 30)     34  
  ( 33 to 36 )  
  35  
  ( 31 to 39 )  
CD4 percent at week 28 (n=95, 30)     34  
  ( 33 to 36 )  
  34  
  ( 31 to 38 )  
CD4 percent at week 72 (n=88, 30)     33  
  ( 32 to 35 )  
  34  
  ( 30 to 38 )  
CD4 percent at week 96 (n=88, 30)     33  
  ( 32 to 35 )  
  34  
  ( 30 to 38 )  
CD4 percent at week 100 (n=85, 29)     35  
  ( 33 to 37 )  
  35  
  ( 32 to 39 )  
CD4 percent at week 104 (n=0, 27)     NA  
  ( NA to NA ) [1]
  36  
  ( 32 to 40 )  
CD4 percent at week 108 (n=82, 28)     35  
  ( 33 to 37 )  
  34  
  ( 30 to 38 )  
CD4 percent at week 120 (n=0, 28)     NA  
  ( NA to NA ) [2]
  37  
  ( 32 to 42 )  
CD4 percent at week 124 (n=0, 27)     NA  
  ( NA to NA ) [3]
  35  
  ( 31 to 39 )  
[1] Week 104 is not a designated time point for Arm A.
[2] Week 120 is not a designated time point for Arm A.
[3] Week 124 is not a designated time point for Arm A.

No statistical analysis provided for CD4 Percent Over Time



7.  Secondary:   HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time   [ Time Frame: Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124. ]

Measure Type Secondary
Measure Title HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time
Measure Description No text entered.
Time Frame Arm A week 0, 8, 12, 24, 28, 72, 96, 100 and 108; Arm B week 0, 8, 12, 24, 28, 72, 96, 100, 104, 108, 120, and 124.  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Any participant who received at least one study vaccine/placebo and with non-missing HIV-1 viral load.

Reporting Groups
  Description
Arm A QHPV Participants received three doses of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 0, 8, and 24 and an additional dose at week 96.
Arm B Placebo/QHPV Participants received three doses of the placebo at week 0, 8, and 24 and additional dose of the quadrivalent human papillomavirus vaccine (QHPV) (Types 6, 11, 16, 18) at week 96, 104 and 120.

Measured Values
    Arm A QHPV     Arm B Placebo/QHPV  
Number of Participants Analyzed  
[units: participants]
  96     30  
HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time  
[units: Log10(copies/mL)]
Log Mean ( 95% Confidence Interval )
   
Log10(RNA) at study entry (n=96, 30)     2.7  
  ( 2.5 to 2.9 )  
  2.6  
  ( 2.3 to 2.9 )  
Log10(RNA) at week 8 (n=92, 30)     2.8  
  ( 2.6 to 3.0 )  
  2.8  
  ( 2.5 to 3.1 )  
Log10(RNA) at week 12 (n=93, 30)     2.7  
  ( 2.6 to 2.9 )  
  2.8  
  ( 2.5 to 3.2 )  
Log10(RNA) at week 24 (n=94, 29)     2.8  
  ( 2.6 to 2.9 )  
  2.7  
  ( 2.4 to 3.1 )  
Log10(RNA) at week 28 (n=95, 30)     2.7  
  ( 2.6 to 2.9 )  
  2.8  
  ( 2.4 to 3.1 )  
Log10(RNA) at week 72 (n=87, 30)     2.7  
  ( 2.5 to 2.8 )  
  2.7  
  ( 2.4 to 3.1 )  
Log10(RNA) at week 96 (n=88, 28)     2.6  
  ( 2.4 to 2.8 )  
  2.4  
  ( 2.1 to 2.6 )  
Log10(RNA) at week 100 (n=84, 29)     2.6  
  ( 2.4 to 2.8 )  
  2.4  
  ( 2.1 to 2.6 )  
Log10(RNA) at week 104 (n=0, 27)     NA  
  ( NA to NA ) [1]
  2.4  
  ( 2.0 to 2.7 )  
Log10(RNA) at week 108 (n=87, 28)     2.6  
  ( 2.4 to 2.7 )  
  2.5  
  ( 2.1 to 2.8 )  
Log10(RNA) at week 120 (n=0, 28)     NA  
  ( NA to NA ) [2]
  2.3  
  ( 2.0 to 2.6 )  
Log10(RNA) at week 124 (n=0, 27)     NA  
  ( NA to NA ) [3]
  2.3  
  ( 1.9 to 2.6 )  
[1] Week 104 is not a designated time point for Arm A.
[2] Week 120 is not a designated time point for Arm A.
[3] Week 124 is not a designated time point for Arm A.

No statistical analysis provided for HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time




  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information